This site is intended for healthcare professionals

FDA extends the PDUFA date for tenapanor for the control of serum phosphorus in patients with CKD on dialysis.-Ardelyx, Inc.

Read time: 1 mins
Last updated:1st May 2021
Published:1st May 2021
Condition: Hyperphosphataemia
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest